Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL

Jonathan Brammer, MD

Published: Thursday, Nov 09, 2017

Jonathan Brammer, MD, hematologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma (CTCL).

SELECTED
LANGUAGE

SEE ALL VIDEOS FROM: Jonathan Brammer, MD

View more on OncLive TV >>>

Trending Now

CLL Research Explores Feasibility of Time-Limited Treatment

MPNs Pioneer Highlights Long-Lasting Role of Interferon

Ibrutinib Plus CAR T-Cell Therapy Boosts Response in CLL

Expert Highlights Encouraging PFS Data With Maintenance Ixazomib in Multiple Myeloma

Eng Highlights Important Treatment Considerations in mCRC

Ibrutinib Established as Standard for Older CLL Patients

New Data Further Demonstrate PARP Inhibitor Impact in Ovarian Cancer

Novel Combination Shows Early Efficacy in Ovarian Cancer

Expert Highlights PARP Inhibitor Advancements in Ovarian Cancer, Points to Future Combos

Related Videos

Dr. O'Malley on Folate-Receptor Alpha as a Biomarker in Ovarian Cancer

Dr. Ai on the FDA Approval of Mogamulizumab in CTCL

Dr. Rogers on Reducing Risk of Tumor Lysis Syndrome in CLL

Dr. Mims on FDA Approval of Ivosidenib in Patients With AML

View Conference Coverage

2019 Genitourinary Cancers Symposium

2019 Transplantation and Cellular Therapy Meetings

2019 Winter Lung Cancer Conference

2019 SGO Winter Meeting

Online CME Activities

Title	Expiration Date	CME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic Leukemia	Feb 28, 2019	0.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application	Feb 28, 2019	2.0